ClinicalTrials.gg
CompletedNCT03661164Updated Sep 11, 2018

Iontophoretic Transepithelial Corneal Cross-linking in Pediatric Patients

An observational study in Keratoconus, sponsored by Luca Buzzonetti. Completed. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2018-09-11.

Sponsored by Luca Buzzonetti · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
22
Ages
8 Years to 18 Years
Sex
All
01

Study summary

To report three year follow up in pediatric patients with keratoconus after iontophoretic transepithelial corneal cross-linking (CXL) to assess preoperative factors that may influence ectasia progression

Read the detailed description

Purpose: To report three year follow up in pediatric patients with keratoconus after iontophoretic transepithelial corneal cross-linking (CXL) to assess preoperative factors that may influence ectasia progression.

Methods: Thirthyfive eyes of 22 consecutive pediatric patients (mean age 14.3±2.5 years) with keratoconus are evaluated in this retrospective study. Subgroup A and B are made up in function of progression in maximum K (Kmax,) defined as steepening of 1.0 diopter or more recorded three year after CXL. Corrected distance visual acuity (CDVA), spherical equivalent, topographic cone location, Kmax, posterior elevation of the thinnest point and thinnest point are evaluated. A paired Student t test is used to compare preoperative and 12, 24, and 36 month postoperative da-ta. A P value \<0.05 was considered significant.

02

Conditions studied

  • Keratoconus

Browse trials for

03

In context

Keratoconus

312 studies on the registry are indexed under Keratoconus; 56 are open to participants now.

This study's enrollment of 22 is below the median of 130 across 96 observational studies indexed under Keratoconus.

Browse Keratoconus studies →

Lead sponsor

Luca Buzzonetti is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 18 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Thirtyfive eyes of 22 consecutive pediatric patients (5 female and 17 male; mean age 14.3±2.5 [SD] years; range, 9 to 18 years) affected by keratoconus (diagnosis established accord-ing to global consensus on keratoconus and ectatic diseases) who underwent transepithelial corneal cross-linking by iontophoresis are enrolled in this retrospective study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

clinical diagnosis of Keratoconus age \< 18 years at the treatment iontophoretic corneal cross linking performed at least 3 years before

Exclusion criteria

Exclusion Criteria:

age > 18 years at the treatment

I

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
22 participants (actual)
Patient registry
No

Interventions

  • Procedurecorneal cross linking

    Iontophoretic corneal cross linking

06

What researchers measure

Primary outcomes

  1. : Preoperative Kmax

    Simulated maximum K (Kmax) is calculated by a Sirius Scheimpflug camera (CSO, Firenze, Italy) by averaging the axial curvature from the fourth to the eighth Placido rings of the flattest and steepest meridians (the amplitude of the zone taken into consideration, therefore has a vari-able diameter depending on the curvature of the cornea, and the principal meridians are not nec-essarily 90 degrees away)

    Time frame: 3 years

  2. posterior elevation of the thinnest point

    posterior elevation of the thinnest point is measured by a Sirius Scheimpflug camera (CSO, Firenze, Italy)

    Time frame: 3 years

  3. cone location

    The topographic cone location is assessed at the preoperative visit as follows : central for cor-neas having maximum K located within the central 3 mm and paracentral for corneas having maximum K located within the central 3 to 5 mm.

    Time frame: 3 years

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03661164
Lead sponsor
Luca Buzzonetti
Responsible party
Luca Buzzonetti (Head of the Ophthalmology Department, Bambino Gesù IRCCS Children's Hospital, Rome, Italy, Bambino Gesù Hospital and Research Institute) — Sponsor-investigator
First posted
Sep 7, 2018
Start date
May 1, 2013
Primary completion
Jun 30, 2015
Completion
Jun 30, 2015
Last update
Sep 11, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion